Cirrhosis News and Research RSS Feed - Cirrhosis News and Research

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Potential treatment target identified for fatty liver disease

Potential treatment target identified for fatty liver disease

Two proteins, p38 gamma and p38 delta, control the accumulation of fat in the liver, a process linked to the development of insulin resistance and diabetes, which are common outcomes of obesity. These findings are presented in an article published by researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC). [More]
Cistus extracts attack HIV and Ebola viruses

Cistus extracts attack HIV and Ebola viruses

Scientists at the Helmholtz Zentrum München discover that extracts of the medicinal plant Cistus incanus (Ci) prevent human immunodeficiency viruses from infecting cells. Active antiviral ingredients in the extracts inhibit docking of viral proteins to cells. Antiviral activity of Cistus extracts also targets Ebola- and Marburg viruses. [More]
Drinking extra 2 cups of coffee per day may reduce cirrhosis risk by 44%

Drinking extra 2 cups of coffee per day may reduce cirrhosis risk by 44%

Regular consumption of coffee was linked with a reduced risk of liver cirrhosis in a review of relevant studies published before July 2015. [More]
EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Bristol-Myers Squibb today announced that the European Commission has approved the expanded use of Daklinza, a first-in-class oral, once-a-day pill used in combination with other treatments as an option for adult patients with chronic hepatitis C virus infection who are co-infected with HIV or who have had a prior liver transplant. [More]
Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. [More]
STAT4 variant predicts HBV IFNα response

STAT4 variant predicts HBV IFNα response

Variation in the STAT4 gene is associated with response to interferon (IFN)α therapy in patients with hepatitis B e antigen-positive chronic hepatitis B virus infection, suggests research published in Hepatology. [More]
Study outlines new model to help predict age-related response to hepatitis B vaccine

Study outlines new model to help predict age-related response to hepatitis B vaccine

Physicians have known for years that patients respond differently to vaccines as they age. There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine. [More]
Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese. [More]
AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection. [More]
Hepatitis C virus linked to increased risk of developing Parkinson's disease

Hepatitis C virus linked to increased risk of developing Parkinson's disease

The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the December 23, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]
Findings show promising evidence for creating broad-spectrum antiviral

Findings show promising evidence for creating broad-spectrum antiviral

UW researchers working in collaboration with Kineta Inc. and the University of Texas at Galveston have shown that making a drug-like molecule to turn on innate immunity can induce genes to control infection in several -known viruses. [More]
Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Prophylaxis treatment can protect children who receive liver transplants from HBV-infected donors

Researchers have found that a prophylaxis treatment can prevent new-onset hepatitis B in children who receive liver transplants from donors who were previously infected with hepatitis B virus (HBV) but had successfully cleared the virus. [More]
New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

New therapeutic target can prevent abnormal blood vessel growth that causes gastrointestinal bleeding

A study by IRB Barcelona and IDIBAPS reveals a therapeutic target to prevent the development of the many abnormal blood vessels that cause gastrointestinal bleeding—the main complication in cirrhosis. [More]
Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

Quest Diagnostics performs RNA testing on patient specimens to detect more cases of HCV

In its commitment to provide diagnostic insights that enhance patient care and outcomes, Quest Diagnostics will automatically perform molecular testing on all patient specimens whose antibody screening results indicate hepatitis C virus infection, and remove standalone positive antibody screening as a test option. [More]
Combining medications may increase HBsAg loss in HBV patients

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial. [More]
Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

Combination of antiviral medications can eradicate HCV infection in patients with advanced liver disease

A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the study was co-led by investigators at Beth Israel Deaconess Medical Center and Intermountain Medical Center and published online Nov. 17 in The New England Journal of Medicine. [More]
Researchers reveal new technique to grow human hepatocytes in the laboratory

Researchers reveal new technique to grow human hepatocytes in the laboratory

In new research appearing in the prestigious journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to creating bio-artificial liver support for patients awaiting transplantations. [More]
Fewer than 1 in 3 UK hospitals employ full-time doctors specialized in liver medicine

Fewer than 1 in 3 UK hospitals employ full-time doctors specialized in liver medicine

Despite rising rates of alcohol- and obesity-related liver disease, fewer than 1 in 3 UK hospitals employ a full-time liver specialist [More]

New drug combination may reduce need for complex regimens to treat hepatitis C

The prognosis for people with hepatitis C has improved dramatically in the last few years, thanks to the introduction of direct-acting anti-viral medications, including Harvoni (the brand name for a combination of ledipasvir and sofosbuvir) and Viekira Pack (a mix of ombitasvir, paritaprevir, ritonavir and dasabuvir). [More]
Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease. [More]
Advertisement
Advertisement